{"entity":{"id":"elena-garralda","kind":"person","name":"Elena Garralda","aka":[],"tldr":"Elena Garralda leads one of Europe's largest phase 1 units.","summary":"Elena Garralda is Director of the Early Drug Development Unit (UITM) at the Vall d'Hebron Institute of Oncology (VHIO) in Barcelona, one of Europe's largest phase 1 units. Her specialisms are phase 1 trials, immuno-oncology and novel modalities, including bispecific antibodies and antibody-drug conjugates. She runs first-in-human trials of ADCs, bispecifics, cell therapies and immunotherapies. Her papers include the Nature Medicine phase 1 trial of OMO-103, a MYC-targeting agent, in solid tumours, a study of the cytokine agent NIZ985 alone and with an anti-PD-1 agent in advanced solid tumours or lymphoma, and the ARROW phase 1/2 study of pralsetinib in RET fusion-positive non-small-cell lung cancer. Her publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Garralda%20E%5BAuthor%5D%20phase%20I"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["bispecific-antibody","adc"],"targets":[],"drugs":[],"companies":[],"institutions":["vall-dhebron"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Early Drug Development Unit (UITM), VHIO","institutionId":"vall-dhebron","specialisms":["Phase 1 trials","Immuno-oncology","Novel modalities"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Garralda%20E%5BAuthor%5D%20phase%20I"}],"papers":[{"title":"MYC targeting by OMO-103 in solid tumors: a phase 1 trial","journal":"Nature Medicine","year":2024,"doi":"10.1038/s41591-024-02805-1"},{"title":"Phase I/Ib study evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of NIZ985 monotherapy and in combination with an anti-PD-1 agent in patients with advanced solid tumors or lymphoma","journal":"European Journal of Cancer","year":2026,"doi":"10.1016/j.ejca.2026.116899"},{"title":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study","journal":"The Lancet Oncology","year":2021,"doi":"10.1016/s1470-2045(21)00247-3"}],"orcid":"0000-0002-4412-7842"},"route":"/people/elena-garralda/","neighbours":{"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"}],"institution":[{"id":"vall-dhebron","kind":"institution","name":"Vall d'Hebron University Hospital / VHIO","route":"/institutions/vall-dhebron/"}]}}